In 4T1 tumor-bearing BALB/c mice, intravenous administration of PNP-D-mAb reduced α-SMA+ CAFs by 62% and collagen I by 45%, while doubling DOX penetration depth in solid tumor, offering a promising strategy for treating CAF-rich solid tumors. This evidence concerns the gene ACTA1 and neoplasm.